文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

经会阴超声引导近距离放疗治疗外照射后局部复发前列腺癌的前瞻性2期试验(NRG肿瘤/RTOG-0526)

A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-10-09

这项前瞻性多中心2期试验纳入外照射后局部复发的前列腺癌患者,评估挽救性低剂量率近距离放疗后晚期胃肠及泌尿生殖系统不良事件。92例可分析患者中12例(14%)发生晚期3级不良事件,未超过预设的不可接受阈值;V100是唯一预测晚期不良事件的因子。

要点

  • 挽救性低剂量率近距离放疗后晚期3级胃肠/泌尿生殖不良事件发生率为14%,无4级或5级治疗相关不良事件。
  • 较高的V100预测晚期不良事件发生(OR 1.24,95%CI 1.02-1.52,P=.03)及更早发生时间(HR 1.18,95%CI 1.03-1.34,P=.02)。
  • 既往外照射剂量和间隔时间等治疗前变量均未预测晚期不良事件。

核心结论

  • 本前瞻性多中心试验报告了外照射后复发接受挽救性低剂量率近距离放疗的结局,晚期3级不良事件发生率未超过不可接受阈值。
  • 唯一预测晚期不良事件的因子是反映植入剂量的V100。
  • 疗效结局将在至少5年随访时报告。

研究设计与样本

  • 前瞻性2期试验(NCT00450411),2007年5月至2014年1月从20个中心注册100例患者,其中92例可分析。
  • 入组条件为外照射前低危或中危前列腺癌、外照射后>30个月活检证实复发、前列腺特异性抗原<10 ng/mL且无区域/远处病变。
  • 主要终点为近距离放疗后9至24个月发生的3级或以上晚期治疗相关胃肠或泌尿生殖不良事件,预设≤10%为可接受、≥20%为不可接受。
  • 所有事件按美国国家癌症研究所不良事件通用术语标准3.0版分级。
  • 采用多变量分析探讨治疗前或治疗变量与不良事件的关联。

主要发现

  • 92例可分析患者中位随访54个月(范围4-97),中位年龄70岁(四分位距65-74)。
  • 初始Gleason评分为7者占48%,外照射中位剂量74 Gy(四分位距70-76),距本次治疗中位间隔85个月(四分位距60-119)。
  • 研究入组时仅16%接受雄激素剥夺治疗。
  • 12例(14%)发生晚期3级胃肠/泌尿生殖不良事件,无治疗相关4级或5级不良事件。
  • 较高的V100预测晚期不良事件发生(OR 1.24,95%CI 1.02-1.52,P=.03)及更早发生时间(HR 1.18,95%CI 1.03-1.34,P=.02);既往外照射剂量和间隔时间等治疗前变量均未预测晚期不良事件。

关键数值与推荐

  • 主要终点预设晚期3级或以上胃肠/泌尿生殖不良事件≤10%为可接受、≥20%为不可接受。
  • 实际观察到的晚期3级胃肠/泌尿生殖不良事件为14%(12/92例可分析患者)。
  • V100每增加一个单位,晚期不良事件发生的OR为1.24(95%CI 1.02-1.52,P=.03),首次发生时间的HR为1.18(95%CI 1.03-1.34,P=.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Only retrospective data are available for low-dose-rate (LDR) salvage prostate brachytherapy for local recurrence after external beam radiation therapy (EBRT). The primary objective of this prospective phase 2 trial (NCT00450411) was to evaluate late gastrointestinal and genitourinary adverse events (AEs) after salvage LDR brachytherapy. METHODS AND MATERIALS: Eligible patients had low- or intermediate-risk prostate cancer before EBRT and biopsy-proven recurrence >30 months after EBRT, with prostate-specific antigen levels <10 ng/mL and no regional/distant disease. The primary endpoint was grade 3 or higher late treatment-related gastrointestinal or genitourinary AEs occurring 9 to 24 months after brachytherapy. These AEs were projected to be ≤10%, with ≥20% considered unacceptable. All events were graded with National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Multivariate analyses investigated associations of pretreatment or treatment variables with AEs. RESULTS: One hundred patients from 20 centers were registered from May 2007 to January 2014. The 92 analyzable patients had a median follow-up of 54 months (range, 4-97) and a median age of 70 years (interquartile range [IQR], 65-74). The initial Gleason score was 7 in 48% of patients. The median dose of EBRT was 74 Gy (IQR, 70-76) at a median interval of 85 months previously (IQR, 60-119). Only 16% had androgen deprivation at study entry. Twelve patients (14%) had late grade 3 gastrointestinal/genitourinary AEs, with no treatment-related grade 4 or 5 AEs. No pretreatment variable predicted late AEs, including prior EBRT dose and elapsed interval. Higher V100 (percentage of prostate enclosed by prescription isodose) predicted both occurrence of late AEs (odds ratio, 1.24; 95% confidence interval, 1.02-1.52; P = .03) and earlier time to first occurrence (hazard ratio, 1.18; 95% CI, 1.03-1.34; P = .02). CONCLUSIONS: This prospective multicenter trial reports outcomes of salvage LDR brachytherapy for post-EBRT recurrence. The rate of late grade 3 AEs did not exceed the unacceptable threshold. The only factor predictive of late AEs was implant dosimetry reflected by V100. Efficacy outcomes will be reported at a minimum of 5-year follow-up.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Crook JM, Zhang P, Pisansky TM, et al. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys. 2018. PMID: 30312717. doi:10.1016/j.ijrobp.2018.09.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。